Mitsubishi UFJ Asset Management Co. Ltd. Has $219.58 Million Stock Holdings in Medtronic PLC $MDT

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Medtronic PLC (NYSE:MDT) by 7.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,518,931 shares of the medical technology company’s stock after purchasing an additional 170,772 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Medtronic were worth $219,575,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. 1248 Management LLC acquired a new stake in shares of Medtronic during the 1st quarter worth about $26,000. Twin Tree Management LP bought a new position in Medtronic in the 1st quarter valued at about $29,000. Activest Wealth Management lifted its position in Medtronic by 3,577.8% during the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after acquiring an additional 322 shares during the last quarter. Hughes Financial Services LLC bought a new stake in shares of Medtronic during the first quarter worth approximately $32,000. Finally, Investment Management Corp VA ADV boosted its holdings in shares of Medtronic by 144.2% during the first quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock worth $36,000 after acquiring an additional 238 shares during the period. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Up 2.4%

Shares of MDT stock opened at $92.22 on Friday. Medtronic PLC has a fifty-two week low of $79.29 and a fifty-two week high of $99.37. The stock’s fifty day moving average price is $94.20 and its two-hundred day moving average price is $89.96. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. The company has a market cap of $118.29 billion, a PE ratio of 25.41, a P/E/G ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.Medtronic’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date was Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is presently 78.24%.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Mizuho lifted their price target on Medtronic from $98.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Argus increased their price objective on Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, August 26th. Wells Fargo & Company boosted their target price on shares of Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, August 20th. The Goldman Sachs Group decreased their price target on shares of Medtronic from $82.00 to $81.00 and set a “sell” rating on the stock in a research note on Wednesday, October 1st. Finally, Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Sunday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $102.82.

Insider Activity at Medtronic

In related news, Director William R. Jellison acquired 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average price of $92.37 per share, with a total value of $230,925.00. Following the purchase, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.